undefined

Sponsors

 

PLATINUM SPONSOR

 

   
                        undefined

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers. For more information, please visit www.affimed.com.

   
 

GOLD SPONSOR

     
                                                                                                                             undefined

Glycostem is a clinical-stage company, leader in Natural Killer (NK) cell commercialization, harvesting the power of allogeneic cells like Natural Killer (NK) cells - oNKord® - in the field of cellular immunotherapy. Over the last 10+ years staff at Glycostem has innovated, developed and clinically tested naked NK-cells as one of the first companies worldwide. Using its proprietary expansion and differentiation platform, Glycostem produces large amounts of effector cells from Umbilical Cord Blood stem cells. Products are composed of high-quality, pure and active cells.

   
               undefined

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

   
 

SILVER SPONSOR

     
  undefined

Innate Pharma est une société de biotechnologie dédiée à l'amélioration du traitement des cancers grâce à des anticorps  thérapeutiques. Elle est spécialisée en immuno-oncologie, une approche d’immunothérapie novatrice qui vise à rétablir la capacité du système immunitaire à reconnaitre et éliminer les cellules tumorales. Innate Pharma développe des anticorps ayant le potentiel d'adresser un grand nombre de cancers en fort besoin médical.

                                                                                                                                                                                                                                                                                                      
  undefined

JLB publishes original experimental and clinical research that provides new insights into the function of leukocytes and/or stromal cells at the molecular, structural, cellular and systemic level.  The Journal scope includes all leukocytes and/or leukocyte products, together with associated stromal cells studied in vitro and in the context of innate and adaptive immunity, development, homeostasis, host-pathogen interactions, immunotherapy, and immunopathogenesis.

   
 

          

            undefined

 

Bio-Techne® unites some of the most distinguished brands within Life Sciences including R&D Systems®, Novus Biologicals®, Tocris®, ProteinSimple® and Advanced Cell Diagnostics®. Together we deliver innovative research technologies and high-quality reagents to the field of Immunology. Our brands work collaboratively to support researchers by providing the instruments, custom manufacturing, and testing services they require to further scientific discovery.

   
 

BRONZE SPONSOR

     
          undefined Headquartered on the campus of the Moffitt Cancer Center, Tampa, Florida, Vycellix™, Inc., is a closely-held immunotherapy-focused, discovery company with the mission to fundamentally impact the challenges that currently prevail in the area of cell & gene based-therapies.  The Company is engaged in the development of proprietary approaches for cell-based immunotherapeutic products and to improve patient outcomes.  Vycellix is leveraging its assets to develop an early-stage pipeline of multifaceted, next-generation NK cell therapies targeting hematological malignancies and solid tumors, including its RONK™ (Retargeted Optimized NK cell) therapy.